IMNM Earnings Date: Nov 5, 2026 (Estimated) — Immunome, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IMNM's next earnings date?
Immunome, Inc. (IMNM) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.61 on revenue of $153,846.
How did IMNM do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Immunome, Inc. posted EPS of -$0.65 versus the -$0.51 estimate, a miss of 27.5%. Revenue was $0 against a $166,667 estimate. The stock's 1-day post-earnings move was +6.6%.
How much does IMNM stock move after earnings?
IMNM beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.51 | -0.65 | -27.45% | $0 | ❌ Miss | +6.63% | +4.99% | -4.88% |
| 2026-05-12 | Q1 2026 | -0.56 | -0.48 | +14.29% | $0 | ✅ Beat | -2.16% | -13.35% | -19.08% |
| 2026-03-03 | Q4 2025 | -0.60 | -0.75 | -25.00% | $0 | ❌ Miss | +4.55% | +1.49% | +4.22% |
| 2025-11-06 | Q3 2025 | -0.55 | -0.65 | -18.18% | $0 | ❌ Miss | -1.68% | +6.52% | +26.71% |
| 2025-08-06 | Q2 2025 | -0.51 | -0.50 | +1.96% | $4.0M | ✅ Beat | -5.64% | -4.30% | +0.57% |
| 2025-05-12 | Q1 2025 | -0.57 | -0.52 | +8.77% | $2.9M | ✅ Beat | +6.43% | +8.04% | +28.28% |
| 2025-03-19 | Q4 2024 | -0.72 | -1.28 | -77.78% | $2.7M | ❌ Miss | +1.05% | -17.27% | -7.70% |
| 2024-11-13 | Q3 2024 | -0.56 | -0.78 | -39.29% | $2.9M | ❌ Miss | -3.88% | -19.50% | +8.54% |
Showing last 8 quarters.